share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  2024/09/09 18:15

Moomoo AI 已提取核心訊息

NeuroSense Therapeutics has successfully completed the in-life phase of its nine-month non-rodent toxicity study for drug candidate PrimeC. The study, which was initiated in November 2023 following discussions with the U.S. Food and Drug Administration (FDA) regarding trial design, has yielded positive results.The successful completion of this toxicity study aligns with the company's regulatory strategy and provides further validation of PrimeC's long-term safety profile, marking a significant milestone in the drug's development pathway.
NeuroSense Therapeutics has successfully completed the in-life phase of its nine-month non-rodent toxicity study for drug candidate PrimeC. The study, which was initiated in November 2023 following discussions with the U.S. Food and Drug Administration (FDA) regarding trial design, has yielded positive results.The successful completion of this toxicity study aligns with the company's regulatory strategy and provides further validation of PrimeC's long-term safety profile, marking a significant milestone in the drug's development pathway.
NeuroSense Therapeutics成功完成了其九個月非齧齒動物毒性研究的在研階段,該研究針對藥物候選PrimeC。該研究於2023年11月在與美國食品藥品監督管理局(FDA)討論試驗設計後啓動,取得了積極的結果。這一毒性研究的成功完成與公司的監管策略一致,並進一步驗證了PrimeC的長期安全性,標誌着該藥物開發過程中的一個重要里程碑。
NeuroSense Therapeutics成功完成了其九個月非齧齒動物毒性研究的在研階段,該研究針對藥物候選PrimeC。該研究於2023年11月在與美國食品藥品監督管理局(FDA)討論試驗設計後啓動,取得了積極的結果。這一毒性研究的成功完成與公司的監管策略一致,並進一步驗證了PrimeC的長期安全性,標誌着該藥物開發過程中的一個重要里程碑。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息